Drug intelligence / Profile preview

IMB5043

Development stage: Preclinical
Lead developer: Institute of Medical Biotechnology, Chinese Academy of Medical Sciences
Modality: Small Molecules
Administration: Intraperitoneal

Overview

IMB5043 is a synthetic small molecule compound characterized by a pyridazinone and thiophene scaffold. It is currently under investigation for its antineoplastic properties, specifically targeting non-small cell lung cancer (NSCLC) that has developed resistance to cisplatin. The compound exerts its cytotoxic effects by concurrently activating apoptosis and autophagy pathways within cancer cells. By inducing these programmed cell death mechanisms, IMB5043 aims to overcome the therapeutic limitations of traditional platinum-based chemotherapies in advanced lung cancer settings.

Beyond the preview

Go deeper on IMB5043.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMB5043.

Explore the full profile